News & Updates

Pertuzumab plus high-dose trastuzumab shows promise for selected patients with HER2-positive MBC

04 Dec 2023

Treatment with pertuzumab plus high-dose trastuzumab appears to confer survival benefits in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy, according to the phase II PATRICIA study.

Pertuzumab plus high-dose trastuzumab shows promise for selected patients with HER2-positive MBC

04 Dec 2023

Ciprofloxacin on par with metronidazole for pouchitis

04 Dec 2023

A propensity-matched study has found no significant difference in the effectiveness of ciprofloxacin, metronidazole, or combination therapy in the real-world setting for an initial episode of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis.

Ciprofloxacin on par with metronidazole for pouchitis

04 Dec 2023

Ensifentrine improves lung function, cuts exacerbations in COPD

04 Dec 2023 by

The novel, selective, dual PDE*3 and PDE4 inhibitor ensifentrine improved lung function and reduced exacerbations in individuals with chronic obstructive pulmonary disease (COPD), findings from the ENHANCE**-1 and ENHANCE-2 trials have shown.

Ensifentrine improves lung function, cuts exacerbations in COPD

04 Dec 2023

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

02 Dec 2023

Avacopan, when added to background induction therapy with rituximab, is as efficacious as a prednisone taper in terms of inducing remission at week 26 and is associated with a higher rate of sustained remission at week 52 in patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, according to the phase III ADVOCATE trial.

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

02 Dec 2023

Immunosuppression does not raise risk of overall, cancer mortality

01 Dec 2023

Use of immunosuppressants does not appear to increase the incidence of all-cause and cancer mortality in patients with noninfectious ocular inflammatory disease (OID) over a median follow-up of 10 years, a recent study has shown.

Immunosuppression does not raise risk of overall, cancer mortality

01 Dec 2023

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

01 Dec 2023

Previous exposure to immune checkpoint inhibitors (ICIs) does not appear to worsen COVID-19 outcomes but may even improve them in patients with cancer, according to a study.

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

01 Dec 2023

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

01 Dec 2023 by

Treatment with seladelpar significantly improves serum markers of cholestasis, including alkaline phosphatase (ALP) and total bilirubin (TB), and reduces pruritus in patients with primary biliary cholangitis (PBC) who are at risk for disease progression, according to the RESPONSE trial presented at The Liver Meeting 2023.

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

01 Dec 2023

NT-proBNP elevations during BP treatment a red flag for kidney function decline

30 Nov 2023

Higher baseline and 1-year increases in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels among individuals receiving blood pressure (BP)-lowering medications are associated with subsequent declines in estimated glomerular filtration rate (eGFR), according to a study.

NT-proBNP elevations during BP treatment a red flag for kidney function decline

30 Nov 2023

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

30 Nov 2023 by

Treatment with dupilumab reduces the use of systemic corticosteroids (SCS) in children with moderate-to-severe asthma, regardless of exacerbation history, according to a post hoc analysis of the VOYAGE and EXCURSION trials presented at APSR 2023.

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

30 Nov 2023

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023 by

The oral, dual peroxisome proliferator-activated receptor-α/δ agonist elafibranor improves biomarkers of cholestasis and quells itching in patients with primary biliary cholangitis, while having an acceptable safety profile, as shown in the phase III ELATIVE study.

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Pertuzumab plus high-dose trastuzumab shows promise for selected patients with HER2-positive MBC

Pertuzumab plus high-dose trastuzumab shows promise for selected patients with HER2-positive MBC

Ciprofloxacin on par with metronidazole for pouchitis

Ciprofloxacin on par with metronidazole for pouchitis

Ensifentrine improves lung function, cuts exacerbations in COPD

Ensifentrine improves lung function, cuts exacerbations in COPD

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

Immunosuppression does not raise risk of overall, cancer mortality

Immunosuppression does not raise risk of overall, cancer mortality

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

NT-proBNP elevations during BP treatment a red flag for kidney function decline

NT-proBNP elevations during BP treatment a red flag for kidney function decline

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

Elafibranor for primary biliary cholangitis scores high in phase III trial

Elafibranor for primary biliary cholangitis scores high in phase III trial